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The study of autoimmunity mediated by immunoglobulin E (IgE) autoantibodies, which 
may be termed autoallergy, is in its infancy. It is now recognized that systemic lupus 
erythematosus, bullous pemphigoid (BP), and chronic urticaria, both spontaneous and 
inducible, are most likely to be mediated, at least in part, by IgE autoantibodies. The 
situation in other conditions, such as autoimmune uveitis, rheumatoid arthritis, hyper-
thyroid Graves’ disease, autoimmune pancreatitis, and even asthma, is far less clear but 
evidence for autoallergy is accumulating. To be certain of an autoallergic mechanism, it 
is necessary to identify both IgE autoantibodies and their targets as has been done with 
the transmembrane protein BP180 and the intracellular protein BP230 in BP and IL-24 in 
chronic spontaneous urticaria. Also, IgE-targeted therapies, such as anti-IgE, must have 
been shown to be of benefit to patients as has been done with both of these conditions. 
This comprehensive review of the literature on IgE-mediated autoallergy focuses on 
three related questions. What do we know about the prevalence of IgE autoantibodies 
and their targets in different diseases? What do we know about the relevance of IgE 
autoantibodies in different diseases? What do we know about the cellular and molecular 
effects of IgE autoantibodies? In addition to providing answers to these questions, 
based on a broad review of the literature, we outline the current gaps of knowledge in 
our understanding of IgE autoantibodies and describe approaches to address them.
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iNTRODUCTiON
Friend or Foe? This is the major question that the immune system must address in every individual 
from the time of conception, through the development of the fetus and the child, right into adulthood. 
But sometimes it gets this wrong and raises an inappropriate immunological response against self. 
Although there are several types of autoimmunity this review will address solely immunoglobulin E 
(IgE)-mediated autoimmunity. Because its mechanisms have much in common with classical allergy 
involving exogenous allergens, such as grass pollen or house dust mites, IgE-mediated autoimmunity 
is generally termed “autoallergy” and the target molecules of the response are called “autoallergens.”
Although the presence of an allergic antibody has been postulated since the innovative serum 
transfer experiment of Prausnitz and Kustner in 1921 (1), it was not until 1967 that this antibody 
was characterized as IgE (2–4). IgE, which is the least abundant immunoglobulin isotype and found 
only in mammals, signals through 2 types of Fcε receptor, the high-affinity receptor, FcεRI, which is 
found primarily on mast cells and basophils, and the low-affinity receptor, FcεRII or CD23, a C-type 
TAble 1 | Percentage of patients in which immunoglobulin E (IgE) 
autoantibodies have been detected in various diseases.




Asthma n.a. n.a. (17, 18)











double stranded DNA (dsDNA), 
IL-24
0–80% (23)
Graves disease TPO, muscle autoantigens 67% (24, 25)
Multiple sclerosis 
(MS)
Small myelin protein-derived 
peptides
n.a. (26)









dsDNA, Sm, SS-A/Ro, SS-B/
La, APEX, MPG, CLIP4, ANA, 
RNP, nucleosome, specific IgE, 
acidic ribosomal P2 protein
3.6–82% (28)
Uveitis Retinal S antigen 69% (29)
n.a., not assessed.
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lectin, which is found on mature B cells, activated macrophages, 
eosinophils, follicular dendritic cells, and platelets. The primary 
role of IgE is held to be host defense, particularly initiating the 
expulsion of parasitic worms (helminths) and environmental 
substances, such as toxins, venoms, irritants, and xenobiotics.
Although IgE has a well-documented role in classical 
allergy to exogenous allergens, this review will address only 
IgE-mediated autoimmunity. It will focus on three related 
questions: what do we know about the prevalence of IgE 
autoantibodies and their targets in different diseases? What do 
we know about the relevance of IgE autoantibodies in different 
diseases? What do we know about the cellular and molecular 
effects of IgE autoantibodies? In addition to providing answers 
to these three questions, based on a comprehensive review of 
the literature, we outline the current gaps of knowledge in our 
understanding of IgE autoantibodies and describe approaches 
to address them.
wHAT DO we KNOw AbOUT THe 
PRevAleNCe OF ige AUTOANTibODieS 
AND THeiR TARGeTS iN DiFFeReNT 
CONDiTiONS?
Within a decade of its discovery, reports began to incriminate 
IgE as a possible contributor to the pathogenesis of several 
chronic inflammatory disorders, such as rheumatoid arthritis 
(RA) (5–7), bullous pemphigoid (BP) (8, 9), atopic dermatitis 
(AD) (10), and systemic lupus erythematosus (SLE) (11, 12). 
More recently, IgE-mediated autoallergy has been suggested 
for other disorders including chronic spontaneous urticaria 
(CSU) (13, 14) and chronic inducible urticaria (CindU) (15). 
The conditions in which IgE autoantibodies have been detected, 
which are summarized in Table  1, will now be considered in 
more detail.
Atopic Dermatitis
Decades before the discovery of IgE, it was reported that human 
dander extract can elicit immediate-type skin reactions in patients 
with severe atopy and that this skin sensitivity could be passively 
transferred with serum (30–35). Many years later, the analysis 
of the presence of IgE autoantibodies in sera from patients with 
various manifestations of atopy and other autoimmune disorders 
indicated that IgE reactivity against a variety of autoantigens 
occurred most frequently in AD patients. IgE autoreactitvy has 
first been found and described in AD (36), where IgE autoanti-
bodies are very frequent (23–91%) (19) and especially present in 
severely affected patients (37–39). IgE autoantibodies had been 
identified directed against Keratinocytes (40) and a broad variety 
of autoantigens (41), including, e.g., human protein manganese 
superoxide dismutase (38), thioredoxin (42), DFS70/LEDGF 
(43), and Hom s 1–5 (44, 45).
Interestingly, this phenomenon has already been seen in very 
young infants of less than 1 year where 15% of the children with 
atopic eczema mounted IgE autoreactivity and raised in the age 
group of 2–13 years with moderate to severe AE and total IgE 
serum levels higher 1,000 kU/L up to 80% (46).
Systemic lupus erythematosus
In SLE, several IgE autoantigens have been described (28, 47), and 
their occurrence is frequent. In a study of 92 SLE patients (48), 29 
(32%) had antinuclear-IgE antibodies. No such antibodies were 
found in a parallel healthy control group. Sub-analysis of the IgE 
autoantibodies in the 29 positive patients showed reactions with 
nucleosomes (79.3%), double stranded DNA (dsDNA) (48.3%), 
SS-A/Ro (48.3%), SS-B/La (18.7%), Sm (48.3%), and RNP 
(62.1%). In a multicentre study of 196 SLE patients (49), more 
than 50% showed autoreactive IgE to one or more of the four 
common SLE nuclear autoantigens, dsDNA, SS-A/Ro, SS-B/La, 
and Sm. This figure rose to around 74% in patients with active 
disease where autoreactive IgE to dsDNA was most prevalent 
with an incidence of 63%. From these findings, Dema and col-
leagues (49) suggest that the presence of autoreactive IgE, and 
in particular dsDNA-specific IgE, in SLE, may be a reasonable 
clinical indicator of increased disease activity. This conclusion is 
supported by a study that showed that disease flares rates were 
higher in SLE patients with demonstrable circulating IgE-anti-
dsDNA antibodies than in those without (50).
Because approximately half of SLE patients do not have 
demonstrable IgE antibodies to the common nuclear autoanti-
gens, the prevalence of IgE autoantibodies to other autoallergens 
has been explored. One study showed high levels of IgE autoan-
tibodies to APEX nuclease 1, N-methylpurine-DNA glycosylase 
and CAP-Gly domain-containing linker protein family member 4 
in some SLE patients but not healthy controls. These autoantigens 
were unique in that they seemed specific targets of IgE autoan-
tibodies but not autoantibodies of the IgG class (49). In another 
study, 31% of 90 SLE patients displayed IgE antibodies against 
human P 2 proteins, an antigen that has also been described to be 
TAble 2 | Percentage of patients with bullous pemphigoid showing 
immunoglobulin E (IgE) reactivity to BP180.
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cross-reactive with other members of the ribosomal P 2 protein 
family, which are minor allergens in fungal allergy (51).
Finally and importantly, IgE to Ro/SSA, a ribonuclearprotein 
autoantigen has been suggested to be relevant for fetal loss by 
mothers with SLE (52). This is of special interest as IgG-anti-Ro/
SSA antibodies are known to be associated with neonatal lupus 
(congenital heart block, neonatal transient skin rash, hematologi-
cal and hepatic abnormalities). However, they are suggested not 
to negatively affect other gestational outcomes, and the general 
outcome of these pregnancies is good when managed by experi-
enced multidisciplinary teams (53).
bullous Pemphigoid
Bullous pemphigoid is an autoimmune blistering disease that 
mainly affects elderly patients. It is the most common pemphi-
goid disorder accounting for around 80% of all pemphigoid 
cases (28). IgG, IgA, and IgE autoantibodies are directed against 
two hemidesmosomal proteins, the transmembrane protein BP 
antigen 2 (BP180, type XVII collagen) and the intracellular BP 
antigen 1 (BP230) (22, 54, 55). Binding of autoantibodies leads to 
a complex inflammatory response involving complement activa-
tion, the infiltration of inflammatory cells, and the subsequent 
release of reactive oxygen species and distinct proteases that 
finally mediate subepidermal splitting (56).
Immunoglobulin E autoantibodies against BP180 target 
mainly the 16th non-collagenous domain (BP180 NC16A) (54, 
57) although BP180 epitopes outside the NC16A domain have also 
been described to be recognized by IgE (58). That IgE-anti-BP180 
is functional was demonstrated by the ability of serum from BP 
patients to sensitize mast cells and basophils for BP180-induced 
histamine release (59). The percentage of BP patients with IgE-
anti-BP180 autoantibodies, shown in Table 2, varied substantially 
in the different reports. The reason in this variation is likely to be 
due to the different test systems used, i.e., ELISA or immunoblot-
ting, and the use of diluted or undiluted patient sera.
Several studies were able to detect IgE autoantibodies against 
the intracellular BP230 autoantigen. Engineer et  al. reported 
IgE-anti-BP230 without detection of BP180-specific IgE autoan-
tibodies in 100% of six BP patients (67). In contrast, other studies 
revealed IgE-anti-BP230 and IgE-anti-BP180 autoantibodies 
in 67% of 67 sera (61) and 50% of 32 sera (68). IgE-anti-BP230 
reactivity was associated with local eosinophil accumulation (61), 
with disease activity (69) and correlated with total IgE serum 
levels (68, 70).
Other Autoimmune blistering Disorders
Pemphigus vulgaris (PV) is another severe autoimmune bullous 
skin disease and is primarily associated with IgG against desmo-
glein 3 (dsg3), a desmosomal adhesion protein. However, raised 
IgE in these patients has also been reported (71). Intercellular 
IgE deposits were detected in the epidermis of 37 patients with 
acute onset of the disease, and IgE-anti-dsg3 was detected more 
frequently in the sera of patients with acute onset, compared to 
chronic-active PV (72). Spaeth and colleagues reported dsg3-
reactive IgE in the serum of 13% of 15 patients with acute onset, 
11% of 18 patients with chronic-active, and none of 8 patients 
with remittent PV patients (73).
In mucus membrane pemphigoid, one of four patients showed 
IgE reactivity to the gamma2 subunit of laminin-332 (74). In 
endemic pemphigus foliaceus, IgE-anti-desmoglein 1 was found 
in 81% of 143 patients with fogo selvagem (75), and serum levels 
of IgE against LJM11, a major immunogenic component of sand 
fly salivary gland antigens, were significantly higher compared to 
controls (76).
In summary, reports in pemphigus are limited, but IgE reactiv-
ity seems to be more prevalent in the endemic form of pemphigus 
foliaceus than in PV.
Chronic Urticaria
An important role of IgE and FcεRI reactions was postulated 
in both CSU and CindU for several decades (77) before it was 
finally confirmed by the successful treatment of the disease with 
anti-IgE (omalizumab) (14, 15, 78). Although specific IgE against 
classical common allergens, i.e., aeroallergens and food allergens 
(79–82), or to less common allergens such as fungi (83, 84) can 
be detected in some patients with CSU, they are not regarded as 
pathophysiologically relevant for the development of the signs 
and symptoms of CSU (81, 85–87).
Perhaps the first evidence of autoreacitivitiy in CSU came 
with the clinical observation that CSU patients have high rates of 
thyroid diseases (88). Detailed analysis of CSU patients with thy-
roid pathology led to the detection of IgE anti-thyroidperoxidase 
(TPO) autoantibodies. Almost 20 years ago, Bar-Sela and cow-
orkers reported the detection of IgE-anti-TPO in a female CSU 
patient who also had Hashimoto’s thyroiditis (89). More recently, 
elevated levels of IgE-anti-TPO were reported in 61% of 478 
CSU patients (13). However, other studies found only 13–17% 
of 23 patients (90) and 10% of 20 patients (91) to have IgE-anti-
TPO, while a further study failed to find IgE-anti-TPO in 23 CU 
patients (92). The most likely explanation for these differences is 
the use of different assay systems, for example direct ELISA vs 
capture ELISA, and the interference of IgG autoantibodies against 
TPO (93). Functional relevance was suggested as flow cytometry 
analysis showed CD203c induction in a dose-dependent man-
ner in basophils sensitized with serial additions of TPO in CU 
patients having high specific IgE to TPO (94).
Beside thyroid diseases, the prevalence of individual autoim-
mune diseases in chronic urticaria is increased in general (≥1% 
in most studies vs ≤1% in the general population). In a review, 
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the rates of comorbidity were ≥1% for insulin-dependent diabe-
tes mellitus, RA, psoriasis, and celiac disease, ≥2% for Graves’ 
disease, ≥3% for vitiligo, and ≥5% for pernicious anemia and 
Hashimoto’s thyroiditis. Interestingly, >15% of CSU patients have 
a positive family history for autoimmune disease (95).
A recent review investigated also the correlation of chronic 
urticaria with other autoimmune diseases such as SLE. The preva-
lence of CSU and CSU-like rash in SLE was investigated from 42 
independent studies. Comorbidity in adult patients reportedly 
ranged from 0 to 22% and 0.4 to 28%, respectively (urticarial vas-
culitis: 0–20%). In children with SLE, CSU was reported in 0–1.2% 
and CSU-like rash in 4.5–12% (urticarial vasculitis: 0–2.2%) (96). 
Specifically, significantly higher levels of IgE-anti-dsDNA, but 
not corresponding IgG levels, have also been found in a study of 
85 chronic urticaria patients (97). Furthermore, basophils from 2 
out of 9 of these patients exhibited degranulation in response to 
dsDNA, indicating functional relevance of these autoantibodies.
Beside these IgE antibodies that target antigens known in 
autoimmune diseases, patients with CSU can also develop 
IgE autoantibodies against probably disease-specific antigens. 
Schmetzer et al. found more than 200 IgE autoantigens in patients 
with CSU that were not found in healthy controls (98). Of the 
31 IgE autoantigens detected in more than 70% of patients, 
8 were soluble or membrane-bound and expressed in the skin 
and IgE autoantibodies to IL-24 were found in all patients with 
CSU. In vitro studies showed functional relevance, and clinically 
IgE-anti–IL-24 levels showed an association with disease activity. 
Detailed analysis of the remaining identified IgE targets had not 
been provided yet.
Other Diseases
In many diseases, single or few reports have indicated a presence 
or potential role of autoreactive IgE.
Autoimmune Uveitis
Beside IgG autoantibodies, in autoimmune uveitis specific IgE to 
retinal S antigen was positive in 69% of 32 patients. In contrast, 
patients suffering from bacterial uveitis, as well as the healthy 
controls were negative for autoantibodies to retinal S antigen (29). 
Furthermore, IgE, IgG, and IgA anti-Galectin-1 (Gal-1) antibod-
ies were increased in sera from patients with autoimmune uveitis 
and toxoplasmic retinochoroiditis compared to healthy controls 
(99). Both, anti-Gal-1 IgE and IgG antibodies were associated 
with progressive disease and poor disease outcome.
Rheumatoid Arthritis
A role of IgE antibodies in RA was first suggested several decades 
ago (27, 100). Antinuclear antibodies of the IgE class were found 
in 60% of 20 RA patients with neutropenia, whereas only 16% of 
RA patients without neutropenia had IgE antibodies of similar 
specificity (27). Anti-citrullinated protein antibodies are sug-
gested to be highly specific and predictive for RA. In a study from 
Schuerwegh and colleagues, evidence for IgE directed against 
citrullinated protein was proposed (101), but later the paper was 
retracted (102). In recent times, no valid studies regarding this 
topic have been published.
Multiple Sclerosis
A role of IgE antibodies in the disease was suggested, despite 
the fact that there was no association between MS and allergies 
(103). In a study from Mikol and colleagues in 26 MS patients, a 
total of 128 peptides showed some IgE reactivity (mean 4.9 per 
subject), compared to 59 among the 15 controls (mean 3.9 per 
subject) (26). A detailed analysis of short, unique myelin protein-
derived peptides (SUMPPs) revealed that for several SUMPPs, 
MS patients had significantly more reactive IgE, whereas for 
other SUMPPs, there was no significant difference between MS 
subjects and controls. The authors speculated that IgE reactive 
against CNS target antigens may have diagnostic and pathogenic 
significance.
Hyperthyroid Graves’ Disease
The presence of IgE autoantibodies in Grave’s disease was first 
proposed 40 years ago (104). Elevation of serum IgE ≥ 170 U/mL 
was found in up to 36% of the patients (105–108), but not in 
another study (109). Furthermore, there was immunohisto-
chemical evidence for IgE involvement in Graves’ orbitopathy 
(110). Studies regarding specific IgE autoantibodies in thyroid 
disease showed IgE class TPO autoantibodies in 13 of 18 Graves’ 
and in 12 of 17 Hashimoto patients (24) and muscle autoanti-
gens in thyroid associated ophthalmopathy (25). Evidence for a 
functional relevance of these IgE autoantibodies was shown by 
Raikow and colleagues, who showed that serum IgE is elevated 
in connection with certain stages of rapid dysthyroid orbitopathy 
progression (111).
Autoimmune Pancreatitis
Elevated total IgE levels are frequent in patients with autoimmune 
pancreatitis (21, 112), and it was recently suggested that analysis of 
total IgE in serum might be useful in the differentiation between 
autoimmune pancreatitis and pancreatic carcinoma (113). 
Nevertheless, IgE specific targets remain currently unknown, 
although there may be cross-reactivity with environmental anti-
gens, as patients with higher IgE levels and with allergic diseases 
were more likely to have onset in March, April, May, August, 
September, or October (21).
Asthma
Autoallergic mechanisms have been proposed in murine models 
of asthma (17, 114). In human asthma, approximately 50% of 
patients with non-allergic asthma react to intradermal injec-
tion of autologous serum, indicating the presence of circulating 
vasoactive factors and suggesting the possibility of an autoreactive 
mechanism (18). In one patient with corticosteroid-dependent 
asthma associated with aspirin sensitivity, the presence of circu-
lating IgE antibodies against 55 and 68 kDa platelet antigens has 
been described (115). Overall, autoallergy in asthma has not been 
studied in detail in humans so far.
Allergic Rhinoconjunctivitis
There is very limited evidence for IgE autoreactivity in allergic 
rhinoconjunctivitis. IgE antibodies from allergic individuals 
that bind to natural and recombinant birch profilin also bind 
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to human profilin (16). Similar cross-reactivity was shown for 
human acidic ribosomal P2 protein in individuals sensitized to 
Aspergillus fumigatus P2 protein (116).
Diseases in which ige Autoantibodies 
were looked for but Not Found
In chronic rhinosinusitis with nasal polyps no IgE autoreactivity 
to epithelial antigens, or anti-IgE IgG, has been detected, despite 
extensive tests (117).
wHAT DO we KNOw AbOUT THe 
RelevANCe OF ige AUTOANTibODieS iN 
DiFFeReNT DiSeASeS?
IgG-mediated autoimmune diseases occur in up to 9% of the 
population (118). Whether or not other immunoglobulin sub-
types, including IgE, are critically involved in the pathogenesis 
of autoimmune diseases is largely unknown for most diseases. In 
contrast, polyreactive natural antibodies, which are not antigen-
specific, can often detect self-antigens with low affinity. Most of 
these natural antibodies belong to the isotypes IgM, IgG3, and 
IgA, and these unspecific antibodies, even if they can bind to 
self-antigens, are thought to be protective, rather than harmful 
(119, 120). There is also some published evidence for the exist-
ence of natural IgE antibodies against pancreatic cancer cells 
(121) and conserved biotinylated-enzyme molecules present in 
many organisms, such as Anisakis simplex, Toxocara canis, Ascaris 
suum, and Culex quinquefasciatus (122, 123). While there are 
currently no data available on the role and relevance of natural 
IgE antibodies and how they could affect disease activity, there is 
some published evidence for a role of antigen-specific IgE against 
self in different diseases. For some diseases, there is only a single 
report on the potential role for auto-IgE. As reviewed above, in 
PV, high concentrations of serum IgE autoantibodies have been 
detected, and a strong correlation between dsg3-reactive IgE has 
been observed in patients with acute disease onset, indicating a 
role for auto-IgE in pemphigus (72). In patients with MS, there 
are some data indicating that IgE against CNS target antigens 
may have a pathogenic significance, particularly if other peptide-
specific, potentially blocking immunoglobulins are absent (26). 
In other autoimmune diseases or diseases in which autoimmunity 
is thought to play a role, some more information on the potential 
role of auto-IgE has been published.
Atopic Dermatitis
Although the pathogenesis of AD is still not completely under-
stood, it is generally accepted that the underlying etiology is 
multifactorial, including environmental factors, impaired skin 
barrier function, and a hyper-immune activation (124). The role 
and relevance of autoimmunity in AD is as of yet unclear. In AD 
patients, many autoantigens can be detected, and IgE against self 
is highly prevalent (125, 126). Whether these auto-IgE antibodies 
indeed contribute to disease activity and severity or are merely 
bystanders cannot be concluded at present (125, 126). There is 
some evidence, however, that is suggestive of a pathogenic role for 
IgE against self in AD. Tang and colleagues have summarized this 
evidence and conclude that IgE autoreactivity is of importance 
in the pathogenesis of AD, especially because autoreactivity has 
been identified in various in vitro and direct clinical experiments 
across distinct study populations (19). Furthermore, significant 
associations between auto-IgE levels in AD patients and disease 
severity have been reported (37, 38), while a further two reports 
show a trend, but no significance for such a correlation (41, 46). 
In contrast, one investigation did not identify a correlation (39).
If auto-IgE is importantly involved in AD pathogenesis, 
treatment with anti-IgE antibodies should be able to improve 
symptoms. Because of the above mentioned investigations, omali-
zumab has been widely used in treatment refractory AD patients 
and many case reports and case series have been published. Two 
recent systematic reviews on the use of omalizumab in AD both 
come to the conclusion that anti-IgE treatment can be beneficial 
in the treatment of AD, but that larger clinical trials are missing 
to fully support this statement (127, 128).
Systemic lupus erythematosus
Autoreactive IgE against a number of different antigens has been 
reported in SLE (see respective section above). In many investiga-
tions, a close correlation between levels of auto-IgG and auto-
IgE in the same patients has been shown, making it difficult to 
estimate the contribution of auto-IgE to the pathology of SLE (49, 
51, 129, 130). However, Henault and colleagues reported that the 
concentration of IgE anti-dsDNA correlates with disease severity 
and is likely to contribute to disease pathology independent from 
IgG anti-dsDNA (129). Dema and colleagues similarly show an 
association of the levels of IgE against different autoantibodies 
with SLE, comparable to autoreactive IgG levels (49). The best 
prediction of disease activity was found to be the presence of 
both, dsDNA-specific IgE and IgG, possibly indicating a role for 
auto-IgE in SLE (49).
In a recent publication, Pan and colleagues have shown that SLE 
patients not only have high levels of IgE directed against various 
autoantigens but also strongly decreased numbers of circulating 
basophils, suggesting auto-IgE-dependent basophil activation in 
the blood (131). These authors also stated that basophils from SLE 
patients showed high rates of activation that closely correlated 
with SLE activity. How this correlates with disease mechanisms 
is not clear. Anti-IgE treatment has not been reported in SLE 
patients as of yet.
Bullous Pemphigoid
The largest body of evidence for a pathological role of autoreactive 
IgE in the literature can be found for BP. In those patients present-
ing with specific IgE directed against the autoantigen BP180, a 
correlation of auto-IgE and disease severity has been reported 
(56, 60, 63). Moreover, Freire and colleagues have shown that 
IgE-anti-BP180 cannot only be found in the serum of BP patients, 
but also in the skin, bound to the surface of tissue-resident mast 
cells (132). Furthermore, they show that patient-derived IgE-
anti-BP180 complexes can activate basophils, indicating the 
functionality of these antibodies (132).
In a number of case reports and case series, excellent efficacy 
of treatment with omalizumab has been shown in BP patients 
(133–140). While these findings are highly suggestive of a 
TAble 3 | Summary of chronic inducible urticaria patients showing a complete 








Symptomatic dermographism 58 43 74
Cold urticaria 51 39 76
Solar urticaria 47 34 72
Delayed pressure urticaria 32 29 91
Cholinergic urticaria 21 17 81
Heat urticaria 5 3 60
Vibratory angioedema 1 0 0
Aquagenic urticaria 1 1 100
Total 216 166 77
Data contained in this table were obtained from Ref. (145, 151–153).
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pathogenic role for auto-IgE in BP, controlled clinical trials with 
omalizumab in BP are necessary to prove the efficacy of anti-IgE 
treatment and thus of the relevance of auto-IgE in BP.
Chronic Urticaria
The evidence for a pathogenetic role of auto-IgE in chronic 
urticaria has been extensively discussed in a recent review (141). 
This paper concluded that there are still many aspects of the 
pathologic mechanisms of CSU that need to be resolved, but that 
it is becoming increasingly clear that there are at least two distinct 
pathways, type I (IgE-mediated) and type II (IgG-mediated) 
autoimmunity, both of which contribute to the pathogenesis of 
this complex disease.
Since then, further evidence for a role for auto-IgE in CSU has 
been presented by Schmetzer and colleagues. Overall, more than 
200 autoantigens that are recognized by IgE have been detected 
in CSU patients, and in 80% of more than 1,000 CSU patients, 
IgE-anti-IL-24 was present (98). Furthermore, levels of IgE-
anti-IL-24 in the serum correlated with CSU disease activity, and 
ex vivo, IL-24 was able to activate mast cells after pre-incubation 
with serum from IgE-anti-IL-24 positive patients, indicating a 
biological relevance for IgE-anti-IL-24 in CSU patients (98).
The clinical relevance of IgE in both CSU and CindU has been 
proven in numerous case reports and case series and in a number 
of randomized-controlled trials using the anti-IgE antibody 
omalizumab (142–145). In fact, the first multi-center placebo-
controlled study of omalizumab in CSU, the XCUISITE trial, 
was done in CSU patients who had IgE-anti-TPO (146). In this 
trial, 70% of patients of omalizumab-treated patients, but only 
5% of placebo-treated patients experienced complete protection 
from wheal development, and the onset of omalizumab effects 
was early after the initiation of treatment. This strongly argues 
that the rapid and profound neutralization of auto-IgE by omali-
zumab contributed to its effects and that these IgE autoantibodies 
play a role in the pathogenesis of CSU. Further support for this 
comes from a recent study that showed that serum reactivity 
predicts the time to response to omalizumab therapy in CSU 
patients (147), suggesting that patients with IgG autoantibody-
mediated CSU show delayed responses, whereas patients with 
IgE-autoantibody-mediated CSU have fast onset of improve-
ment. The exact mechanisms by which anti-IgE treatment leads 
to the resolution of symptoms in most CSU patients are, as of yet, 
unclear. Nonetheless, at least in a proportion of CSU patients, the 
massive reduction of autoantigen-specific IgE is likely to be the 
most relevant mechanism.
In CindU, there is also a strong indication for an important role 
of IgE against self. For example, anti-IgE treatment has been shown 
to be highly effective in CindU in numerous case reports and case 
series, as well as in two randomized-controlled trials (Table 3). 
Furthermore, a direct involvement of IgE in some patients with 
CindU has been shown by passive transfer experiments. In cold 
urticaria (148, 149) as well as in symptomatic dermographism 
(150) disease activity was, in some patients, transferable from 
patients to healthy subjects by intradermal injection of patient 
sera. In these investigations, IgE was identified to be the relevant 
serum factor (148–150).
wHAT DO we KNOw AbOUT THe 
GeNeTiC bASiS OF ige-MeDiATeD 
AUTOAlleRGY
In an effort to understand the genetic influence on autoallergic 
diseases, it is best to look first at well-analyzed diseases such as 
SLE, where autoreactive IgE has been known for four decades 
(27). The prevalence of SLE and the presence of new autoreactive 
IgE are remarkably dependent on sex and race being 2.3-fold 
higher in Black persons than in White persons and 10-fold higher 
in females than in males (154). The greater incidence in females 
may be partially explained by the observation that women treated 
with estrogen and progesterone have a 1.34 times higher risk of 
developing SLE flares as compared to placebo treated.
Autoreactive IgE has been assessed in two SLE patient cohorts, 
IgE targeting classical SLE antigens being found in 63.3% of 
patients of French origin but only 52.9% of the patients from 
the United States (49). Most prominent in this study was IgE-
anti-dsDNA but also auto-IgE against other SLE antigens (Sm, 
SSA/Ro, SSB/La). Non-SLE IgE only antigens (APEX, MPG, 
CLIP4) were also found. This autoreactive IgE correlated highly 
significantly with disease activity (SLEDAI score) and reduced 
C3 or C4 levels suggesting that IgE facilitates the amplification of 
autoimmune inflammation (155).
Chronic spontaneous urticaria is another example of an auto-
IgE-mediated disease, where a strong and complex genetic bias 
via multiple alleles exists. These include C5AR1 (156), FPRL1 
(157), FcvarepsilonR1beta (158), TGFbeta1 (159, 160), IgE (161), 
IL-13 (162), histamine N-methyltransferase (163), PTPN-22 
(164, 165), CTLA-4 (166), and ACE (167).
In addition to the well-known loci linked to hypersensitivity 
and atopy, such as PLA2G7, MS4A2, IL4R (168), IL-10 (169), 
IL12RB1 (170), STAT4/6, CTLA-4 (171), and GATA3 (172), recent 
studies identified many new alleles which regulate IgE production 
independent of external stimuli. However, these are often single 
findings, and only a genome-wide screening could weigh these 
findings and determine their relation to atopy, IgE and auto-IgE. 
One genome-wide screening on alleles influencing total IgE level 
identified FCER1A polymorphisms as having most impact, fol-
lowed by RAD50 and STAT6 as the lowest relation (173).
7Maurer et al. IgE Autoantibodies
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 689
One genetic variant has been studied in detail which links 
elevated IgE concentrations to a polymorphism in the IL21R 
gene promoter (174). This −83T–C promoter polymorphism in 
the IL21R gene is linked to a changed response of IgE synthesis to 
IFN-gamma stimulation (175). If IL-21 is knocked-out in murine 
models, IgE production after immunization is increased, while 
IgG subtypes are decreased in otherwise normal animals (176). 
In contrast, loss-of-function of the IL-21R gene in humans leads 
to a severe primary immune defect (177). The difference to the 
murine model is not surprising, given the low degree of homol-
ogy of the IgE system between man and rodent.
In addition to this IL-21 gene variant, environmental recep-
tor encoding genes, such as NOD1 have been linked to asthma 
(178). This opens a crucial new viewpoint on genetics where 
environmental stimuli are related to selected genotypes to explain 
the phenotype. Another example is the β2-adrenoreceptor gene 
promoter polymorphism that determines modulation of IgE 
production as a response to xenobiotics (β2-agonists and gluco-
corticoids) (179).
These examples demonstrate the vast complexity of the genetic 
regulation of IgE synthesis (180). With modern deep sequencing 
strategies there are more and more variants found which change 
the risk for asthma and atopy, and influence IgE level. Sequencing 
of the IL4 gene alone lead to 14 new, previously unrecognized 
polymorphisms in addition to only two known previously (181). 
There are no studies on auto-IgE and HLA polymorphisms. 
However, IgE is involved in antigen uptake via immune com-
plexes and presentation via MHC class II to CD4 cells (44, 182, 
183). Therefore, there is a high likelihood that HLA genotypes 
will be linked to auto-IgE, but the studies need to be done.
wHAT DO we KNOw AbOUT THe 
CellUlAR AND MOleCUlAR eFFeCTS 
OF ige AUTOANTibODieS?
When looking on the effects of IgE autoantibodies, mast cells 
and basophils are usually the focus of attention as they express 
high levels of the high-affinity receptor for IgE (FcεRI). Antigen-
dependent activation of mast cells and basophils via FcεRI is the 
cause of acute allergic reactions induced by the rapid release 
of preformed mediators from granules and subsequent libera-
tion of de novo synthesized lipids, cytokines, and chemokines. 
Yet, mast cells and basophils are not the only cells that express 
FcεRI and, importantly, other receptors such as CD23 (FcεRII) 
and galectin-3 are capable of binding IgE and inducing cellular 
responses. Thus, mast cell and basophil activation may be only 
the tip of the iceberg when considering the biology of IgE 
autoantibodies and their contribution to diseases. In particular, 
the function of CD23 in IgE-dependent sensitization of the 
host to autoallergens, which in turn may further strengthen the 
production of autoreactive IgE might be of great importance in 
the development of autoallergies.
In general, all IgE, whether it is autoreactive or whether it 
recognizes exogenous antigens, can trigger the same cellular 
responses as there is no evidence yet that autoreactive IgE have 
special molecular characteristics that drive certain functions/
responses such as, for instance, cytokinergic activity. However, 
certain activities are not necessarily triggered by autoreactive 
IgE such as the CD23-mediated transepithelial transport of IgE. 
Here, we will focus on IgE-binding receptors with regards to their 
contribution in autoallergy.
effects of ige/Autoantigen on FcεRi 
Signaling
The high-affinity receptor for IgE (FcεRI) consists of one 
IgE-binding α chain, which binds IgE with a very high affinity 
(1010 M−1), but does not contain intracellular signaling motives, 
one transmembrane-spanning β chain, which crosses the 
plasma membrane four times and contains an immunoreceptor 
tyrosine-based activation motive (ITAM), and two identical 
γ chains each containing an ITAM (184). This αβγγ motive is 
mainly expressed by mast cells and basophils although expres-
sion has also been shown in airway smooth muscle cells and 
bronchial epithelial cells of asthmatic patients (185, 186). A 
αγγ version of this receptor can be expressed by a variety of 
other cells including subsets of dendritic cells and monocytes/
macrophages (187–189), eosinophils (190), neutrophils (191), 
and platelets (192, 193). Because of its high affinity for IgE, the 
receptor is occupied by monomeric IgE. When cross-linked by 
a multivalent antigen, it triggers signaling cascades leading to 
the immediate degranulation in mast cells and basophils, i.e., 
the release of preformed mediators from intracellular granules 
and de novo synthesis of lipid mediators such as prostaglandins 
and leukotrienes as well as the production of cytokines and 
chemokines and the expression of various surface markers. These 
include chemokine receptors such as CCR7 on plasmacytoid 
dendritic cells (pDCs) (129) or the selectin CD62L on basophils 
(194) that facilitate the migration of activated cells to local lymph 
nodes, but also co-stimulatory molecules like CD83 and CD86 
on pDCs. Moreover, autoreactive IgE activates pDCs more effi-
ciently and further synergizes with IgG through co-engagement 
of activating FcγRIIa, even in concentrations several orders of 
magnitude below IgG concentrations and drive B cell expansion 
and plasma call differentiation (129, 130). FcεRI engagement by 
IgE and allergen also induces IL-16 in Langerhans cells, a che-
moattractant for CD4+ T cells, dendritic cells, and eosinophils 
(195). Thus, autoreactive IgE may have the capacity to augment 
disease activity in autoimmunity.
Surface bound IgE has been shown to stabilize and enhance 
the surface expression of FcεRI on mast cells and basophils, 
thereby allowing cells to bind more IgE, which in turn may 
lower the threshold for antigen-induced cell activation (196). 
This amplification loop might be of particular importance 
in autoallergic patients who present with increased serum 
and tissue IgE levels. Consistently, treatment with antibodies 
directed against IgE does not only lower serum IgE levels but 
also FcεRI surface expression on dendritic cells, basophils, and 
mast cells (197–199). Moreover, FcεRI-bound IgE promotes 
mast cell survival and migration (200). Interestingly, certain 
IgEs even induce mast cell and basophil degranulation and 
cytokine release in an antigen-independent manner (201). 
Although the in vivo relevance of this “cytokinergic” activity 
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has not been demonstrated yet, it may have an impact in 
autoallergy. Cytokinergic IgE molecules associate with them-
selves and show an enhanced propensity to be polyreactive to 
various autoantigens (202, 203).
FcεRI-bound and antigen cross-linked IgE becomes inter-
nalized rapidly (129, 204). Thus, on the one hand, free serum 
IgE is cleared by dendritic cells and monocytes. On the other 
hand, when cross-linked, autoantigens become internalized 
and are capable of stimulating intracellular pattern recogni-
tion receptors such as TLRs. In pDCs, IgE autoantibodies 
directed against dsDNA become internalized and directed to 
phagolysosomes where TLR9 becomes activated to trigger the 
generation of inflammatory cytokines, such as INF-α, IL-6, 
IL-8, and TNF-α (129). Alternatively, internalized IgE/autoan-
tigen is presented via MHC class-II by basophils, cutaneous 
Langerhans cells, or other dendritic cells in regional lymph 
nodes or local submucosal sites to naïve T cells to induce TH2 
cells (194, 196, 205, 206). In systemic lupus erythematosus 
(SLE), activation of basophils by autoreactive IgE can induce 
the upregulation of CD62L, MHC-II and the B cell-activating 
factor BAFF. Activated basophils then migrate into the sec-
ondary lymphoid organs, where they produce IL-4 and IL-6, 
thereby promoting a TH2 environment with more IL-4 produc-
ing activated T  cells and enhanced B  cell proliferation with 
increased IgG1 and IgE production (194). In addition, CD1c+ 
dendritic cells may have the capacity for cross-presentation of 
internalized antigen to induce cytotoxic CD8+ cells. However, 
this is strongly inhibited by IL-4-producing TH2 cells (207). 
On monocytes, the engagement of FcεRI induces antibody-
dependent cell-mediated cytotoxic activities of the cells rather 
than antibody-dependent cell-mediated phagocytic activities 
(ADCP), which are linked to the engagement of the low-
affinity IgE receptor, CD23 (see below).
In BP, CSU and AD, the degranulation of mast cells and 
basophils contributes to disease manifestations. This, however, 
does not occur in systemic lupus erythematosus patients, who 
lack classical allergic manifestations. A possible mechanism 
for this is the co-engagement of inhibitory receptors such as 
FcγRIIb by autoreactive IgG in SLE (208). Moreover, cross-
linking of FcεRI in monocytes and dendritic cells induces 
“late” anti-inflammatory IL-10, which can attenuate basophil 
and dendritic cell activation and suppresses monocyte 
phagocytic activity (209–211). Additionally, in monocytes, 
FcεRI engagement induces the upregulation of indoleamine 
2,3-dioxygenase (IDO), which inhibits T cell proliferation and 
activates FOXP3+ regulatory T cells through the depletion of 
tryptophan (212).
A soluble version of FcεRI consisting of a single a-chain has 
been described (213). How sFcεRI is generated in  vivo is not 
known so far. In vitro experiments suggest that it is generated 
during cellular FcεRI engagement. sFcεRI may bind to IgE with 
similar affinity as membrane-bound FcεRI and, therefore, might 
serve as a soluble regulator of free IgE and IgE-mediated cellular 
activation. Binding in a 1:1 ratio to IgE, it has the potential to 
prevent IgE from binding to the cellular receptor, and could nega-
tively affect FceRI expression levels. In vitro and in vivo studies 
with sFcεRI show inhibitory properties on mast cell and basophil 
degranulation (214). Its impact in autoallergy, however, needs to 
be determined.
effects of ige/Autoantigen on CD23 
(FcεRii) Signaling
Most studies on the effects of IgE-mediated responses focus 
on mast cells or basophils and FcεRI signaling, as they are 
responsible for the immediate allergic response. However, the 
so-called “low affinity” receptor for IgE, CD23, has important 
functions in positively or negatively regulating IgE synthesis as 
well as antigen presentation to T cells (215). It is expressed on 
various cells including epithelial cells, activated B and T  cells, 
Langerhans cells, plasma cells, monocytes, and eosinophils (196). 
CD23 belongs to the family of C-type lectins, which are calcium-
dependent carbohydrate binding structures and contain three 
lectin domains located on the C-terminal extracellular head of 
the molecule. Interestingly, binding of IgE to the head domains 
seems not to involve carbohydrate structures (216). Although the 
affinity of a single CD23 head for the IgE-Fc is comparably low, 
the combined interaction of all three heads with IgE results in an 
strong binding with an affinity (108–109 M−1) that is comparable 
to that of FcεRI (215). Interestingly, CD23 is prone to shedding 
by disintegrin and metalloproteinase domain-containing protein 
10 (ADAM10) resulting in various soluble forms (monomeric or 
trimeric with varying sizes), all of which are capable to bind IgE 
(214, 217) and are found in autoimmune diseases like SLE where 
auto-IgE has been described (218). Multiple ligands/interaction 
partners other than IgE have been described to interact with 
CD23 and are important for its function including the comple-
ment receptor 2, 3, and 4 (CD21; CD18/CD11b; CD18/CD11c), 
MHC-II, the receptor for vitronectin (αVβ3-integrin) and the 
αVβ5-integrin (215, 219). One important function of CD23 with 
regards to autoallergy is probably associated with the regulation 
of IgE production by B  cells committed to IgE secretion. IgE-
induced engagement of membrane CD23 induces a negative 
feedback while sCD23 (trimeric) through co-ligation of CD21 
enhances IgE production (215). Moreover, CD23 bound IgE-
antigen complexes can be presented to T cells via a process called 
facilitated antigen presentation (FAP). In FAP, the antigen-loaded 
IgE-CD23 gets internalized and loaded onto MHC-II molecules 
for presentation on the B-cells surface (219). A Th2 environment, 
as derived by activation of mast cells and basophils via FcεRII 
activation, may support this by increasing the expression of CD23 
on B cells. Importantly, any activated B cell that expresses CD23, 
can present allergens to T cells independently of the specificity of 
the B cell receptor (BCR). By this, CD23-FAP can lead to epitope 
spreading, a process where the response to one epitope encoun-
tered by the BCR induces epitope-specific immunoglobulin pro-
duction against the allergen internalized by CD23 (215). Epitope 
spreading can occur intra- or intermolecularly and is thought to 
be the driving cause for the development of polyspecific allergies 
to unrelated antigens. It is, therefore, of particular importance 
for the development of autoallergies. Antigen presentation via 
the CD23–MHC-II axis is as efficient as presentation of antigens 
by dendritic cells mediated by FcγRs and by far more efficient 
than BCR internalization (220). This is particularly dangerous 
when epitopes of an autoantigen and a pathogen are very similar 
9Maurer et al. IgE Autoantibodies
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 689
in sequence and/or conformation (molecular mimicry) and IgE 
against the pathogen (IgEPATH) also binds to the autoantigen (221). 
Low-affinity IgEPATH-autoantigen interactions can lead via FAP 
dependent epitope spreading to high affinity auto-IgE. For many 
autoimmune diseases, such as SLE and BP, where IgE autoanti-
bodies have been identified, B  cell epitope spreading has been 
recognized as an important contributor for disease development.
On monocytes and macrophages, engagement of CD23 
induces nitric oxide synthase and proinflammatory cytokines and 
importantly mediates IgE-dependent phagocytosis of targeted 
cells suggesting a use for immunotherapy, for instance in cancer 
(188, 222). Interestingly, auto-IgE to tumor antigens can be found 
in tumor tissue as well as systematically, suggesting a tumor sup-
pressive function of these IgE autoantibodies.
effects of ige/(Auto)Antigen on Galectin-3 
Signaling
Galectin-3 is a secretory lectin containing a carbohydrate rec-
ognition domain connected to a non-lectin linker domain that 
associate to form a pentameric structure like IgM molecules. 
Galectin-3 is expressed by various immune cells including mast 
cells, basophils, neutrophils, monocytes, Langerhans cells, as well 
as T and B cells (196). It can be found in the nucleus, intracellular 
vesicles, or exosomes of expressing cells or gets secreted by a yet 
not fully characterized mechanism (223). Following secretion, 
it interacts with a large variety of cell surface and extracellular 
matrix proteins including IgE and FcεRI. Interestingly though, 
galectin-3 appears to have distinct binding capacities for IgE 
isoforms that are differentially glycosylated, although the con-
sequence of this phenomenon in allergy and autoallergy is not 
clear (224). Because it is capable of binding to IgE and FcεRI, it 
can activate mast cells and other FcεRI-expressing and/or IgE-
loaded cells in an IgE-dependent or independent manner and 
boost mast cell and basophil activation. In autoimmune diseases, 
galectin-3 is often increased in the serum and in tissues and may 
support auto-IgE-induced inflammation. However, most effects 
of galectin-3 on the immune system are independent of its ability 
to crosslink IgE and FcεRI. Its effects and relevance in autoallergy, 
therefore, need to be determined carefully (214, 225).
GAPS OF KNOwleDGe, UNMeT NeeDS, 
AND UNANSweReD QUeSTiONS
Need for improved Detection Methods
There are two different major drawbacks of the tests currently 
used to assess autoreactive IgE. First, different methods show a 
high variability and low reproducibility of IgE reactivity (226). 
This has been best demonstrated using the well characterized BP 
autoantigen BP180-NC16A. An improved ELISA method showed 
a significantly higher frequency of NC16A-specific IgE autoanti-
bodies in the sera of BP patients than previously described (66). 
This study also demonstrated that most BP sera contain both, IgE 
and IgG class autoantibodies specific for NC16A and that IgG 
reactive to the same autoantigen as IgE can mask the detection 
of autoreactive IgE. This is the second major drawback of direct 
ELISA methods. This problem can be addressed by the use of 
indirect ELISA methods, where total IgE is first captured on the 
plate by anti-IgE and labeled autoantigen is used for detection 
(98). This approach, however, also has limitations. Saturation of 
the anti-IgE with non-autoreactive IgE in sera with very high 
total IgE concentrations can lead to the underestimation of 
autoallergen-specific IgE. Also, this method requires recombi-
nant IgE to be able to calculate the specific IgE concentration in 
international units.
Yet unaddressed questions are the relevance of different 
conformational states of IgE, such as the bent-form, that may 
not be detectable by ELISA depending on which anti-IgE is used 
(227). Relevant cross-autoreactive IgE might also be prone to 
oligomerization due to stacking, which may hinder binding to 
capture antibodies.
Finally, autoreactive IgE may be preferentially captured in 
the tissue in patients with high FcεRI expression due to high IgE 
levels. Increased levels of IgE are frequently seen in patients with 
chronic urticaria and in atopic individuals (228, 229). Vice versa, 
as antigen reactivity encoded by the Fab-domain can change also 
the Fc part and, therefore, influence Fc receptor binding, some 
autoreactive IgEs might be over- or underrepresented in the non-
cell bound IgE fraction due to changed FcεRI binding (230). Even 
assays detecting non-autoreactive IgE often fail to show a clinical 
relevance (231). The questions above need to be addressed for 
IgE in general, not only autoreactive IgE, in further studies, and 
improved methods need to be developed.
what leads to the Development of 
Autoantibodies of the ige isotype?
There are several possible mechanisms that might lead to a 
preference of IgE isotype for autoantibodies. Most IgE autoan-
tigens are phosphorylated molecules (97, 232, 233). It has been 
demonstrated that IgG autoantibodies in BP preferably recognize 
a phosphorylated epitope (232, 234). The importance of phos-
phorylation for the development of autoantibodies in general has 
been shown for myeloperoxidase-anti-neutrophil cytoplasmic 
IgG autoantibodies in a mouse model (235). However, further 
studies are needed to assess whether this is a general rule prefer-
ably for IgE autoantigens, or for all autoantigens.
ige Cross-Reactivity Remains largely 
Unexplained
In contrast to IgG and IgA, IgE has, in general, a much higher 
degree of cross-reactivity. This makes the determination of 
antigen-specific IgE difficult. As of now, very little is known about 
cross-reactivity of IgE autoantibodies. One study that performed 
site-directed mutagenesis of an allergenic peptide found that 
even after the mutation of all of the four residues that are mainly 
involved in IgE binding, the IgE still bound, albeit with a 100-fold 
reduced affinity (236). Furthermore, many studies have shown IgE 
cross-reactivity to structurally similar allergens, e.g., sensitization 
to the fungus F. proliferatum may lead to allergy to penicillin (237).
Usually, IgE cross-reactivity is explained by the recognition of 
carbohydrate-containing epitopes such as in cross-reactive IgEs 
against wheat/pollen or latex/hymenoptera proteins (238–241) 
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or between different pollen allergens (242–244). Hierarchies 
of cross-reactivity toward different pollen allergens have been 
established (245).
In latex–pollen–food allergy, a good example of non-
carbohydrate based cross-reactivity, cross-reactive IgE binds to 
latex and maize (246) or other food allergens (247). The antigenic 
epitopes of these allergens are well characterized and show only a 
low degree of sequence homology. The cross-reactivity can only 
be explained by a similar charge distribution, which, in the case 
of IgG, does usually not lead to cross-reactive antibodies (248).
Other examples of IgE cross-reactivity include pollen–food 
allergy, such as apple–birch allergy or pollen–fruit allergy 
(249–253), dog–cat allergy (254, 255), poultry–meat allergy (256), 
fish–chicken allergy (257), birch–oak allergy (258), latex–hyme-
noptera allergy (239–241). IgE cross reactivity to latex and parasites 
like Schistosoma has also been described (259, 260). In mice sen-
sitized to birch pollen that also developed anaphylactic reactions 
to apple, desensitization to birch pollen also provided protection 
from anaphylaxis to apple (261). Similar experiences have been 
reported in allergic patients, where tolerance induction against 
one allergen also reduced reactivity toward other allergens (262). 
While IgE cross-reactivity between classical allergens is much more 
common than previously thought (263), cross-reactivity between 
autoallergens needs to be investigated in future studies.
Unanswered Questions?
Many questions on IgE autoantibodies remain unanswered.
•	 Is IgE to self different from IgE to exogenous antigens in 
terms of its biochemical properties, its glycosylation, or its 
folding?
•	 Where is auto-IgE produced and what B cells are involved?
•	 Does the auto-IgE come from CD5+ B1 B cells of the marginal 
zone of the spleen (poorly negatively selected B cells that often 
produce autoantibodies) or from B cells that were previously 
allergen or pathogen reactive?
•	 Does the production of auto-IgE precede the onset of autoal-
lergic signs and symptoms and when and why does it stop?
These and other questions are currently addressed by ongoing 
research. The answers that will come from these and future stud-
ies will help to better understand the biology and relevance of IgE 
autoantibodies in disease and to develop better approaches for 
the prevention and treatment of autoallergies.
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